Results

1–10 of 11 results for Intravitreal aflibercept injection

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
Low Incidence of Endopthalmitis After Intravitreal Injections in an Office Setting Without Gloves and Drapes With a Modified Technique
Kamal Kishore, MD, MBBS
On Demand Cases, Courses, and Papers
2020
Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA
Nathan C. Steinle, MD
Annual Meeting Talks
2020
Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Study
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2020
Foveal Capillary Perfusion Density Decreases in Diabetics with DME Treated on a Fixed Regimen of Intravitreal Aflibercept Injections Over 24 Months
Brittney Statler, MD
Updates from the Field
2020
Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection: 52-Week Results From PANORAMA
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2019
Evaluation of Treatment of High Risk Proliferative Diabetic Retinopathy With Intravitreal Aflibercept Injection (ELYSIAN)
Victor Hugo Gonzalez, MD
On Demand Cases, Courses, and Papers
2018